Bio-Thera Solutions (688177.SS) Stock Price

Bio-Thera Solutions Price

CLOSED
18.91
​
Market closed

Over the last 9 years Bio-Thera Solutions grew revenue by 91.0% annually, reaching 935.22 M CNY. For Bio-Thera Solutions, the net margin of -35.5% is down versus 9.8% a few years ago. The consensus 12-month price target for Bio-Thera Solutions is 36.92 CNY, about 95.3% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.

Bio-Thera Solutions stock price

Access this data via the Eulerpool API

Bio-Thera Solutions business model & stock analysis

Bio-Thera Solutions Ltd. engages in the research, development, and production of innovative drugs and biosimilar drugs for the treatment of tumours, autoimmune diseases, cardiovascular diseases, other threats to human life, and major health diseases. The company is headquartered in Guangzhou, Guangdong and currently employs 1,189 full-time employees. The company went IPO on 2020-02-21. The firm is committed to the development of a new generation of antibody drugs to treat cancer, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life and health. The firm's main products include adalimumab BAT1406, bevacizumab BAT1706, BAT8001, tocilizumab BAT1806, batifaban BAT2094, BAT8003 and so on.

Frequently asked questions about Bio-Thera Solutions

Analysts currently set an average price target of 36.92 CNY for the Bio-Thera Solutions stock (median: 36.92 CNY), implying +95.3 % versus the latest price. The consensus is based on 5 analyst ratings.

5 analysts currently rate the Bio-Thera Solutions stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Bio-Thera Solutions to generate revenue of 1.28 B CNY and earnings per share of -0.83 CNY.

Converted at the current exchange rate, the Bio-Thera Solutions share trades at 2.51 EUR (18.91 CNY).

The expected revenue of Bio-Thera Solutions is 1.28 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Bio-Thera Solutions is -343.69 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Bio-Thera Solutions is currently -22.78. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bio-Thera Solutions stock.

The price-to-sales ratio (P/S) of Bio-Thera Solutions is currently 6.12. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bio-Thera Solutions stock.

The Eulerpool Quality Score for Bio-Thera Solutions is 2/10.

The ISIN of Bio-Thera Solutions is CNE100003R98. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Bio-Thera Solutions is 688177.SS. The ticker symbol is used to trade Bio-Thera Solutions shares on the stock exchange.

Fair ValueTerminal
19.10 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
786,557.70 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
Feb 21, 2020
ISIN
CNE100003R98
Cusip
Y09077101
Market capitalization
7.83 B CNYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-22.78
P/Ee 2027
-27.81
P/S
P/Se
6.12
EV/EBIT
—
P/B Ratio
20.82
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-44.24 %
Last updated Oct 9, 2026, 1:09 PM

Bio-Thera Solutions Peer Group

Bio-Thera Solutions FIGI

688177:CH · BBG00PNST176688177:CG · BBG00PNST1X7688177:C1 · BBG01GZT7BK7